Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.

HYPOTHESIS An elevated serum α-fetoprotein (AFP) level before orthotopic liver transplant (OLT) is predictive of mortality after OLT for hepatocellular carcinoma (HCC). DESIGN Retrospective analysis of a population-based cohort. SETTING United Network for Organ Sharing registry (2003-2008). PATIENTS We identified 2253 patients who underwent OLT for HCC with available pre-OLT serum AFP values. METHODS Patients were stratified by AFP levels into low (<20 ng/mL), medium (20-399 ng/mL), or high (≥400 ng/mL) groups. Clinical and pathological characteristics were compared among groups. Survival curves were constructed by the Kaplan-Meier method, and univariate and multivariate Cox-regression analysis was performed. RESULTS Of the 2253 patients, 1210 (53.7%), 805 (35.7%), and 238 (10.6%) were in the low, medium, and high AFP groups, respectively. On univariate analysis, the low AFP group demonstrated the best 4-year survival (76%) compared with the medium (65%; P = .001) and high (57%; P < .001) AFP groups. When AFP levels in patients with only stage II HCC underwent assessment, improved survival in the low AFP group was still observed (P < .001). On multivariate analysis, the medium and high AFP groups were associated with higher mortality (hazard ratios, 1.50 [95% confidence interval, 1.19-1.89; P = .001] and 2.11 [1.55-2.88; P < .001], respectively). CONCLUSIONS Serum AFP level is an independent prognostic predictor of outcome after OLT for HCC. The association between serum AFP value and post-OLT survival warrants further investigation to potentially better allocate donor allografts for HCC.

[1]  K. Taketa.  Alpha-fetoprotein: reevaluation in hepatology. , 1990, Hepatology.

[2]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[3]  E. Jaurrieta,et al.  Selection criteria for liver transplantation in early‐stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  N. Perevodchikova,et al.  Embryonal serum alpha-globulin in cancer patients: diagnostic value. , 1967, International journal of cancer.

[5]  C G BERGSTRAND,et al.  Demonstration of a new protein fraction in serum from the human fetus. , 1956, Scandinavian journal of clinical and laboratory investigation.

[6]  Lin Zhou,et al.  The Value of Serum α-Fetoprotein in Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma , 2009, Digestive Diseases and Sciences.

[7]  L. Roberts,et al.  Treatment options for hepatocellular carcinoma , 2008, Expert review of gastroenterology & hepatology.

[8]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[9]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[10]  P. Angus,et al.  Risk factors for liver transplantation waiting list mortality , 2007, Journal of gastroenterology and hepatology.

[11]  R. Wiesner,et al.  The new liver allocation system: Moving toward evidence‐based transplantation policy , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  K. Shirabe,et al.  A comparison of the surgical results in patients with hepatitis B versus hepatitis C‐related hepatocellular carcinoma , 1995, Hepatology.

[13]  M. Manns,et al.  Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[15]  M. Ho,et al.  Liver transplantation for patients with hepatocellular carcinoma. , 2004, Transplantation proceedings.

[16]  J. O'grady,et al.  Liver Transplantation for Malignant Disease: Results in 93 Consecutive Patients , 1988, Annals of surgery.

[17]  Carmine Tinelli,et al.  Predictors of Long-Term Survival After Liver Transplantation for Hepatocellular Carcinoma , 2005, The American Journal of Gastroenterology.

[18]  G. Ioannou,et al.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. , 2008, Gastroenterology.

[19]  L. Pączek,et al.  [Liver transplantation for hepatocellular carcinoma]. , 2003, Polskie Archiwum Medycyny Wewnetrznej.

[20]  Mark S Roberts,et al.  Survival after liver transplantation in the United States: A disease‐specific analysis of the UNOS database , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  D. V. van Thiel,et al.  Hepatic resection versus transplantation for hepatocellular carcinoma. , 1991, Annals of surgery.

[22]  Günter Tusch,et al.  Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients , 1991, World Journal of Surgery.

[23]  Adrian M Di Bisceglie,et al.  Diagnosis of hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[24]  H. El‐Serag,et al.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States , 2001, Hepatology.

[25]  M. Kew.  Tumour markers of hepatocellular carcinoma , 1989, Journal of gastroenterology and hepatology.

[26]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[27]  M. Schwartz,et al.  Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  B. Mailey,et al.  A Disease-Based Comparison of Liver Transplantation Outcomes , 2009, The American surgeon.

[29]  N. Perevodchikova,et al.  Embryonal serum α‐globulin in cancer patients: Diagnostic value , 1967 .

[30]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  H. Bismuth,et al.  Liver Transplantation for Hepatocellular Carcinoma , 1999, Seminars in liver disease.

[32]  U. Valente,et al.  Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis. , 2008, Transplantation proceedings.

[33]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[34]  K. Taketa.  α‐fetoprotein: Reevaluation in hepatology , 1990 .

[35]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[36]  Johnny C. Hong,et al.  Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. , 2008, Archives of surgery.

[37]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[38]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[39]  P. Tangkijvanich,et al.  Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels , 2000, Journal of clinical gastroenterology.

[40]  T. Yanagisawa,et al.  Selection Criteria for PLIF or TLIF , 2012 .

[41]  M. Kudo,et al.  Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. , 2008, Journal of hepatology.